Market Dynamics Driving Blockbuster Momentum

Due to the complexity of clinical development and regulatory approval, many companies are concentrating investment in a small number of key tumor types—multiple myeloma, breast cancer, prostate cancer, renal cell carcinoma (RCC), and non small cell lung cancer (NSCLC)—rather than pursuing areas with fewer competitive agents in the pipeline. By 2024, seven of the 10 highest-revenue oncology companies were U.S.-based, accounting for approximately 57% of U.S. oncology revenue and nearly 30% of global oncology sales. This concentration reflects a deliberate strategy to scale across large, well-validated markets where clinical development pathways and commercial infrastructure are already well established.

Performance within this group continues to be driven by a small number of high-revenue assets. Bristol Myers Squibb, Merck, Johnson & Johnson, and Eli Lilly have each outpaced the broader U.S. oncology market growth, which expanded at ~13% CAGR over this period. In many cases, market leadership is anchored by single multibillion-dollar therapies that support broad portfolio economics. Checkpoint inhibitors remain central to this dynamic, alongside CDK4/6 inhibitors, reinforcing a model in which sustained growth is increasingly tied to early development within foundational treatment classes rather than breadth alone.

Strategies Redefining Oncology Treatment Paradigm

Oncology growth is increasingly shaped by the pace and scale of innovation rather than market expansion alone. Between 2015–2024, approximately 150 New Active Substances (NAS) entered the U.S. oncology market, with solid tumors accounting for nearly two-thirds of approvals. Launch activity increased by nearly 40% in 2020-2024 compared to the prior five years, reflecting sustained investment in indications with both high prevalence and persistent unmet need. Non-small cell lung cancer, breast cancer, non-Hodgkin lymphoma (NHL), and multiple myeloma continue to account for a disproportionate share of approvals, reinforcing their role as focal points for R&D prioritization. The result was more approvals but also heightened competitive intensity.

1. Modality Evolution: Expanding Oncology’s Therapeutic Arsenal
   Oncology innovation has been supported by a gradual but important shift in therapeutic modality. While oncology approvals remain anchored in small molecules and biologics, advanced modalities—which rely on specialized treatment techniques or care settings beyond traditional community oncology—now represent a growing share of new launches. Cell and gene therapies (CAGT) have reshaped treatment expectations in select hematologic malignancies, while antibody drug conjugates (ADC), bispecific antibodies, and radioligand therapies (RLTs) have expanded into a broader set of solid and hematologic tumors. Together, these modalities are extending the population of addressable patients while introducing new complexity into clinical development, access planning, and long-term portfolio strategy.

2. Delivery Innovation: Addressing Affordability and Access
   Oncology innovation has created meaningful clinical value, but it has also increased pressure on delivery systems and patient access. High treatment costs, combined with the operational demands of infusion-based care, continue to constrain capacity across sites of care. In response, innovation is increasingly focused on how therapies are delivered, not only on therapeutic mechanism. The expansion of subcutaneous formulations for established immunotherapies and emerging antibody platforms reflects a broader shift toward improving efficiency, reducing treatment burden, and enabling care delivery outside traditional infusion settings. To date, however, uptake of these approaches in the U.S. has been slow, reflecting reimbursement dynamics, site-of-care economics, and provider workflow inertia. While long-term potential to improve patient experience and ease system-level constraints remains compelling, near-term impact will depend on how effectively manufacturers align clinical value with quality-of-care incentives across providers, payers, and delivery networks.
3. Precision-Driven Segmentation: Carving Out High-Need Patient Niches
   Precision medicine continues to be a core driver of oncology innovation. Approximately one-third of recent NAS approvals have targeted biomarker-defined patient populations, with activity concentrated primarily in solid tumors, such as NSCLC and breast cancer. These launches reflect continued investment in molecularly segmented indications where diagnostic adoption and clinical development pathways are well established. At the same time, biomarker-driven development is increasingly enabling the creation of new niche patient segments alongside continued refinement of existing ones. By targeting previously underserved molecular profiles with high unmet needs, companies are expanding the addressable market for targeted therapies while increasing complexity across development, access, and commercialization. As segmentation becomes more granular, long-term success depends on the ability to scale beyond initial niche populations and integrate diagnostics, evidence generation, and portfolio strategy more effectively.

Impact of Hypercompetition as Innovation Concentrates

The convergence of sustained unmet need, accelerated R&D timelines, and high-target validation has intensified competition across oncology markets. Over the past decade, lifecycle expansion has become the dominant growth strategy in oncology, with more than 500 approvals across NAS and label extensions collectively supporting continued value well beyond initial launch. This pattern is most pronounced in large, established indications such as NSCLC, breast cancer, and multiple myeloma, where successive expansions increasingly function as a primary engine of growth rather than discrete launch events. As a result, leading oncology assets are increasingly managed through a “pipeline in a product” strategy, where value is built both vertically, by moving earlier across lines of therapy, and horizontally, by expanding into new indications and patient populations, rather than through a single discrete launch event.

This dynamic is most visible in established treatment backbones. Checkpoint inhibitors continue to anchor care across multiple tumor types, with rapid progression from later-line settings into earlier lines of therapy. Growth within these classes is now driven less by entry of new mechanisms and more by line of therapy, combination strategies, and incremental differentiation supported by ongoing evidence generation. Similar patterns are emerging across other validated pathways, where multiple modalities compete within overlapping patient populations.

As innovation converges around proven targets, competitive density has increased across major oncology markets, including NSCLC, breast cancer, NHL, and multiple myeloma, where multiple modalities now compete for overlapping patient segments. Late entrants face slower uptake and often face later line-of-therapy utilization, increasing the importance of early positioning and disciplined indication strategy. In this environment, durable commercial success depends on establishing relevance early and sustaining it through coordinated clinical development, lifecycle execution, evidence strategy, and portfolio integration.

Expanding R&D and Accelerating Trial Momentum

Despite increasing competition in the commercial landscape, oncology R&D activity continues to expand, driven by rapid modality innovation and more precise patient segmentation. U.S. oncology trial starts more than doubled between 2020 and 2024, with activity increasingly concentrated in solid tumors. Phase II studies now account for nearly half of all trial initiations, reflecting a development pipeline that is both exploratory and focused on advancing assets toward proof of concept.

Advanced modalities now represent more than a third of active oncology trials. CAGT programs have expanded beyond hematologic malignancies into select solid tumors, while antibody-drug conjugates continue to show the fastest growth in trial activity and remain a focal point for oncology dealmaking. Bi- and multi-specific antibodies are advancing steadily through mid- and late-stage development, and radioligand therapies are gaining earlier lines of therapy that increase the size of the patient population in indications such as prostate and neuroendocrine tumors.

At the same time, despite the relative maturity of the PD-(L)1 class, checkpoint inhibitors remain central to oncology development, accounting for the largest share of ongoing clinical trials. Their continued role as treatment backbones reflects both clinical validation and their importance in combination therapies.

Strategic Imperatives for Market Positioning in a Dynamic Oncology Market

Oncology remains a central driver for biopharma growth, but the conditions required for sustained success are changing. As innovation accelerates and competition intensifies around established targets and treatment backbones, market leadership is increasingly shaped by how effectively organizations execute against clear strategic priorities. Companies that succeed are those that translate innovation into focused development plans, coherent positioning, and sustained adoption rather than relying on participation in high-growth segments alone.

• Portfolio strategy requires greater focus on coherence. The expansion of modalities and targets has increased choice, but it has also increased complexity and diluted returns for unfocused portfolios. Leading organizations are becoming more selective in where they invest, prioritizing franchises and tumor areas where they can build durable relevance across multiple lines of therapy. This requires earlier decisions on portfolio fit, clearer criteria for business development, and tighter alignment between scientific ambition and commercial potential, reinforced by regulatory frameworks that increasingly incentivize the quality and durability of approvals rather than volume alone.
• Lifecycle planning must be established early and managed deliberately. In crowded oncology markets, value is increasingly determined before launch. Decisions around indication strategy, trial design, and evidence generation shape whether an asset achieves differentiation or struggles to gain traction. Treating leading products as long-term growth platforms requires earlier integration of clinical, regulatory, and commercial planning, with clear intent around how initial approvals support future expansion and sustained use.
• Precision strategies must balance focus with scalability. Biomarker-driven development continues to create opportunity, particularly in high unmet need populations, but increasingly narrow targeting raises execution risk. Successful strategies define a clear path from initial niche adoption to broader clinical relevance, supported by integrated diagnostic approaches, efficient development plans, and access strategies that enable uptake beyond early adopters. Precision alone is not sufficient without a credible plan to scale.
• Organizational capacity is emerging as a practical constraint. As the volume and complexity of oncology development grow, execution capacity is emerging as a limiting factor. The ability to prioritize programs, resource launches appropriately, and coordinate across R&D, medical, access, and commercial teams has an increasing role in success. With more assets competing and narrower windows for differentiation, execution capacity increasingly influences whether innovation translates into sustained performance.

As oncology innovation converges around a narrow set of proven scientific pathways, market leadership is no longer defined by innovation alone, but by the ability to execute with discipline. Strong science is now table stakes. It establishes relevance, but it does not guarantee success. What separates leaders is how effectively they translate innovation into focused development choices, clear market positioning, and sustained adoption over time. In crowded markets, outcomes are determined early by indication strategy, lifecycle intent, and the ability to align clinical, regulatory, access, and commercial decisions behind a single coherent plan.

At the same time, competitive intensity is being amplified by strategic convergence across large biopharma, as companies are increasingly pursuing the same limited set of viable paths in oncology. Whether expanding a single asset across indications, assembling portfolios within a small number of tumor areas, or concentrating investment in select advanced modalities, the industry is moving in parallel. Because these options are finite, many organizations are moving in the same direction at the same time, resulting in crowding and compressing the window for differentiation. In this environment, leadership is shaped by clarity of choice. Organizations that commit early, make deliberate tradeoffs, and resist reactive expansion are better positioned to sustain advantage in a market defined by shared direction rather than open opportunity. Contact IQVIA to learn more about how to evaluate oncology opportunities, prioritize effectively, and execute strategies that support long-term performance.